- Home
- BCTX vs LPCN Comparison
BCTX vs LPCN Comparison
Compare BCTX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- LPCN
- Stock Information
- Founded
- BCTX 2014
- LPCN 1997
- Country
- BCTX Canada
- LPCN United States
- Employees
- BCTX N/A
- LPCN N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- LPCN Health Care
- Exchange
- BCTX Nasdaq
- LPCN Nasdaq
- Market Cap
- BCTX 14.4M
- LPCN 16.1M
- IPO Year
- BCTX N/A
- LPCN N/A
- Fundamental
- Price
- BCTX $7.72
- LPCN $2.89
- Analyst Decision
- BCTX Strong Buy
- LPCN Strong Buy
- Analyst Count
- BCTX 1
- LPCN 2
- Target Price
- BCTX $40.00
- LPCN $9.00
- AVG Volume (30 Days)
- BCTX 92.9K
- LPCN 16.6K
- Earning Date
- BCTX 10-28-2025
- LPCN 08-05-2025
- Dividend Yield
- BCTX N/A
- LPCN N/A
- EPS Growth
- BCTX N/A
- LPCN N/A
- EPS
- BCTX N/A
- LPCN N/A
- Revenue
- BCTX N/A
- LPCN $4,208,119.00
- Revenue This Year
- BCTX N/A
- LPCN N/A
- Revenue Next Year
- BCTX N/A
- LPCN N/A
- P/E Ratio
- BCTX N/A
- LPCN N/A
- Revenue Growth
- BCTX N/A
- LPCN N/A
- 52 Week Low
- BCTX $6.00
- LPCN $2.68
- 52 Week High
- BCTX $294.00
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- BCTX 40.75
- LPCN 39.08
- Support Level
- BCTX $7.28
- LPCN $2.86
- Resistance Level
- BCTX $8.82
- LPCN $3.00
- Average True Range (ATR)
- BCTX 0.74
- LPCN 0.11
- MACD
- BCTX 0.58
- LPCN -0.01
- Stochastic Oscillator
- BCTX 60.82
- LPCN 12.28
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.